These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17168450)

  • 21. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
    Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
    Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of non-small cell lung cancer: focus on erlotinib. Foreword.
    Cappuzzo F
    Drugs; 2012 Jun; 72 Suppl 1():1-2. PubMed ID: 22712791
    [No Abstract]   [Full Text] [Related]  

  • 23. [Is it possible to treat bronchial carcinoma without chemotherapy?].
    Pujol JL
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S23-10S26. PubMed ID: 17127957
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
    Böker B; Lüders H; Grohé C
    Pneumologie; 2012 Feb; 66(2):89-95. PubMed ID: 22337328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
    Huang Y; Zhang L; Shi Y; Ma S; Liao M; Bai C; Zhang Q; Wang C; Luo F; Yu S; Qin S; Zhi X; Zhou C
    Jpn J Clin Oncol; 2015 Jun; 45(6):569-75. PubMed ID: 25855621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
    Lim JU; Woo IS; Jung YH; Byeon JH; Park CK; Kim TJ; Kim HR
    Korean J Intern Med; 2014 Nov; 29(6):830-3. PubMed ID: 25378985
    [No Abstract]   [Full Text] [Related]  

  • 28. EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
    Jassem J; Dziadziuszko R
    Lancet Oncol; 2013 Sep; 14(10):916-7. PubMed ID: 23883923
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
    Mok T; Wu YL; Au JS; Zhou C; Zhang L; Perng RP; Park K
    J Thorac Oncol; 2010 Oct; 5(10):1609-15. PubMed ID: 20808255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
    Pennell NA; Yin L; Keshtgarpour M; Ma PC
    J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
    [No Abstract]   [Full Text] [Related]  

  • 31. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.
    Perng RP; Yang CH; Chen YM; Chang GC; Lin MC; Hsieh RK; Chu NM; Lai RS; Su WC; Tsao CJ; Hsia TC; Chen HC; Chen CH; Huang MS; Wang JL; Ho ML; Chung CY; Yu CJ; Chang WC; Kuo HP; Yu CT; Lin ZZ; Kao WY
    Lung Cancer; 2008 Oct; 62(1):78-84. PubMed ID: 18423781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
    Liu GF; Li XF; Yu SN; Miao YY; Zhang SH
    J Cell Physiol; 2019 Apr; 234(4):3445-3457. PubMed ID: 30374969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.
    Lee DH; Kim SW; Suh C; Han YH; Lee JS
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):35-9. PubMed ID: 20182725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.
    Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
    Curr Med Res Opin; 2012 Apr; 28(4):643-50. PubMed ID: 22414178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients.
    Arrieta O; Rios Trejo MA; Michel RM
    J Thorac Oncol; 2009 Aug; 4(8):1043. PubMed ID: 19633484
    [No Abstract]   [Full Text] [Related]  

  • 37. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
    Fuster LM; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
    Berge EM; Aisner DL; Doebele RC
    J Thorac Oncol; 2013 Sep; 8(9):e83-4. PubMed ID: 23945392
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
    J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
    Fiala O; Pesek M; Finek J; Krejci J; Bortlicek Z; Benesova L; Minarik M
    Neoplasma; 2013; 60(2):129-34. PubMed ID: 23259780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.